You searched for "patient"
Understanding Stauffer’s syndrome
Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...Demanding cases or nightmares in uro-oncology? Jan/Feb 2022
When less is more: percutaneous biopsy and tumour seeding in papillary renal cell carcinoma Renal cell carcinoma (RCC) accounted for 2.2% of new cancer diagnoses worldwide in 2018 with over 400,000 new cases and 175,098 deaths [1]. The majority of...A negative ureteroscopy for stone disease: is it acceptable and is it avoidable?
Urinary tract stone disease and the consequent demand for endoscopic intervention in the upper urinary tract is an increasing phenomenon [1]. Although ureteroscopy is generally considered to be associated with low morbidity [2], risks do exist. Recognised complications include urothelial...Virtual reality: a novel approach to pain management during ESWL
Extracorporeal shock wave lithotripsy (ESWL) is a well-established treatment for kidney and ureteric stone disease, employing high-energy shock waves to fragment stones into smaller pieces for passage through the urinary tract. This article explores the application of virtual reality (VR)...
Bladder perforation after augmentation cystoplasty
Delayed bladder perforation is well recognised after augmentation cystoplasty (5-13% of patients) and adult urologists need to be aware of this and identify the best treatment at the time. Mortality rates and re-perforation rates can be up to 25% and...
Sacral agenesis and neurogenic bladder: long-term outcomes of bladder and kidney function
These authors looked at single institution outcomes for sacral agenesis (without spina bifida) with reference to renal function and bladder function. All had urodynamics either at diagnosis (56%) or soon after. Of 43 patients (23 female, 20 male), 37 had...Sexual dysfunction following prostate cancer treatment
Prostate cancer is common with over 52,300 new cases diagnosed annually in the UK; this is expected to rise by 15% between 2023-2025 and 2038-2040 [1]. Radical prostatectomy continues to be the most common form of radical treatment for men...Pelvic floor imaging – a brief synopsis
Background Pelvic floor imaging is an important part of both gastrointestinal and functional urology / urogynaecological departments. Symptoms such as obstructive defecation, incontinence and sphincter complex disorders have a significant impact on patient lifestyle and physical / mental well-being [1,2]....Demanding cases or nightmares in uro-oncology? Jan/Feb 2023
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...
Patterns of relapse and implications for post-nephrectomy surveillance in patients with high-risk NCC-RCC
The natural history of non-clear cell renal cell carcinoma (NCC-RCC) post-nephrectomy with curative intent remains poorly defined. The surveillance protocols are largely dependent on guidelines followed for clear cell RCC (CC-RCC). In this study, the authors evaluated the relapse patterns...
Testosterone supplementation after prostatectomy – journey from bad to good
The role of androgens in the pathogenesis of prostate cancer is quite complex and is not entirely clear yet. Despite several reports suggesting testosterone use is safe in patients diagnosed with prostate cancer, many clinicians are still reluctant to use...
